Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
$3.58
+1.7%
$2.50
$1.51
$12.00
$252.99M1.992.36 million shs565,859 shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$15.00
+0.6%
$16.14
$13.46
$31.04
$445.51M0.88499,021 shs449,428 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.36MN/AN/A4.25 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$6.09
+9.5%
$7.02
$3.84
$11.50
$634.88M1.961.58 million shs2.52 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
+6.02%+42.51%+11.04%+59.28%+44.86%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+5.45%-2.61%-11.41%-41.64%-23.82%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
Personalis, Inc. stock logo
PSNL
Personalis
-3.81%+1.09%-15.50%-33.09%+30.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
$3.58
+1.7%
$2.50
$1.51
$12.00
$252.99M1.992.36 million shs565,859 shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$15.00
+0.6%
$16.14
$13.46
$31.04
$445.51M0.88499,021 shs449,428 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.36MN/AN/A4.25 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$6.09
+9.5%
$7.02
$3.84
$11.50
$634.88M1.961.58 million shs2.52 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
+6.02%+42.51%+11.04%+59.28%+44.86%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+5.45%-2.61%-11.41%-41.64%-23.82%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
Personalis, Inc. stock logo
PSNL
Personalis
-3.81%+1.09%-15.50%-33.09%+30.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
1.50
Reduce$6.0067.64% Upside
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.20
Hold$27.0080.05% Upside
Charming Medical Ltd stock logo
MCTA
Charming Medical
1.00
SellN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
2.57
Moderate Buy$11.5088.83% Upside

Current Analyst Ratings Breakdown

Latest AIRS, PSNL, MCTA, and FLGT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Reiterated RatingNeutral$30.00 ➝ $15.00
4/21/2026
Personalis, Inc. stock logo
PSNL
Personalis
Reiterated RatingSell (D-)
3/5/2026
Personalis, Inc. stock logo
PSNL
Personalis
Lower Price TargetEqual Weight$11.00 ➝ $10.00
2/27/2026
Personalis, Inc. stock logo
PSNL
Personalis
Boost Price TargetBuy$10.00 ➝ $12.00
2/11/2026
Personalis, Inc. stock logo
PSNL
Personalis
Boost Price TargetBuy$12.00 ➝ $13.00
2/9/2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
DowngradeStrong-BuyHold
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
$151.82M1.66$0.02 per share192.80$1.40 per share2.56
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$322.67M1.38N/AN/A$35.10 per share0.43
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
$69.65M9.15N/AN/A$2.94 per share2.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
-$11.67M-$0.19N/AN/AN/A-7.68%-5.01%-2.19%5/8/2026 (Estimated)
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%N/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
-$81.27M-$0.91N/AN/AN/A-116.69%-39.13%-29.31%5/7/2026 (Confirmed)

Latest AIRS, PSNL, MCTA, and FLGT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026Q4 2025
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
-$0.02N/AN/AN/A$39.20 millionN/A
5/7/2026Q1 2026
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23N/AN/AN/A$14.49 millionN/A
3/31/2026Q4 2025
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
-$0.02-$0.02N/A$0.02N/A$33.44 million
3/31/2026Q4 2025
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
-$0.03$0.02+$0.05$0.02$34.93 million$33.44 million
2/27/2026Q4 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$0.02$0.16+$0.14-$0.76$85.38 million$83.34 million
2/26/2026Q4 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.31-$0.26+$0.05-$0.26$17.12 million$17.35 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
N/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
0.58
0.55
0.55
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
5.31
6.48
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/A
6.76
6.61

Institutional Ownership

CompanyInstitutional Ownership
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
91.54%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Personalis, Inc. stock logo
PSNL
Personalis
61.91%

Insider Ownership

CompanyInsider Ownership
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
44.60%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
36.18%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Personalis, Inc. stock logo
PSNL
Personalis
4.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
24070.55 million39.08 millionOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31529.75 million18.99 millionOptionable
Charming Medical Ltd stock logo
MCTA
Charming Medical
4916.94 millionN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
400104.68 million100.28 millionOptionable

Recent News About These Companies

Breaking Down Personalis: 5 Analysts Share Their Views
Personalis (PSNL) Q4 2025 Earnings Call Transcript
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

AirSculpt Technologies stock logo

AirSculpt Technologies NASDAQ:AIRS

$3.58 +0.06 (+1.68%)
As of 03:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. The company's body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$15.00 +0.10 (+0.64%)
As of 03:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Charming Medical stock logo

Charming Medical NASDAQ:MCTA

$29.36 0.00 (0.00%)
As of 05/5/2026 03:30 PM Eastern

We are a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. We offer a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles and practices of TCM, such as the use of herbal ingredients, acupuncture techniques, Tuina massage, and dietary guidance. Operating under the Beauty Lab Group (“Beauty Lab”) brand, our Operating Subsidiaries in Hong Kong offer a wide range of TCM-inspired beauty, wellness, and postpartum therapies and products through our four wellness centers in Hong Kong. Our services are designed to meet diverse health improvement needs, including alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, and other common women’s health conditions. We believe that our TCM-inspired herbal therapies can help balance the female endocrine system and improve women’s constitution and overall health. Additionally, the Operating Subsidiaries offer TCM-inspired therapies tailored to men. We offer a wide range of beauty, wellness, and postpartum services for women with a focus on utilizing TCM approaches in addressing women’s health issues. Our beauty, wellness, and postpartum services include but are not limited to womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, TCM-inspired prenatal massage, and Indonesian traditional abdominal binding. In addition, under the “Beauty Lab” brand, we also offer supplements products, including (i) TCM-inspired supplements products, such as Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets, designed to support uterine health, improve physical weakness, and balance endocrine functions for female customers; and (ii) beauty products, including ginseng soothing anti-allergy moisturizing wash, which provide comprehensive care for skin issues, and scalp health. Moreover, we also offer consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. In March 2025, we launched a franchise model for our Beauty Lab brand, granting exclusive rights to independent third parties (the “Franchisees”) to operate branded beauty and wellness outlets. Franchisees are authorized to offer services such as scalp and hair care and women’s wellness services under the Beauty Lab brand. We derive franchise-related revenue mainly from initial franchise fees, royalty and promotional fees, brand management fees, training and administration fees. As of March 31, 2025 and as of the date of this prospectus, we had 1 and 3 franchisees, respectively. We generated revenue of $6,221,751 and $6,015,375, respectively, and achieved a net income of $1,199,085 and $821,743, respectively, for the years ended March 31, 2025 and 2024. We generated revenue primarily through the following: (i) beauty, wellness, and postpartum services; (ii) sales of products; (iii) consultancy services; and (iv) franchise activities. For the fiscal years ended March 31, 2025 and 2024, the revenue from beauty, wellness, and postpartum services amounted to $5,967,277 and $5,813,814, representing 96.0% and 96.6% of total revenue, respectively. The revenue from sales of products was $207,766 and $88,992 for the fiscal years ended March 31, 2025 and 2024, representing 3.2% and 1.5% of total revenue, respectively. The revenue from consultancy services was nil and $112,569 for the fiscal years ended March 31, 2025 and 2024, representing 0% and 1.9% of total revenue, respectively. The revenue from franchise activities was $46,708 and nil for the fiscal years ended March 31, 2025 and 2024, representing 0.8% and 0% of total revenue, respectively. Our principal executive office is located Hong Kong.

Personalis stock logo

Personalis NASDAQ:PSNL

$6.09 +0.53 (+9.53%)
As of 03:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.